Eli Lilly is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit ...

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...

The move reveals both the power of philanthropic groups to sway legislators and a split in the administration’s coalition.

Key Points Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major competitor in China.

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving ...

Deep-pocketed investors have adopted a bullish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a ...

Key Points Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is ...